The novel mitochondria activator, 10-ethyl-3-methylpyrimido[4,5-b] quinoline-2,4(3H,10H)-dione (TND1128), promotes the development of hippocampal neuronal morphology

Adenosine triphosphate (ATP) is the most vital energy source produced mainly in the mitochondria. Age-related mitochondrial dysfunction is associated with brain diseases. Nicotinamide adenine dinucleotide (NAD(+)) is an essential cofactor for energy production in mitochondria. Here, we examined how the novel NAD(+)-assisting substance, 10-ethyl-3-methylpyrimido[4,5-b]quinoline-2,4(3H,10H)-dione (TND1128), modulates the morphological growth of cultured mouse hippocampal neurons. The morphological growth effect of TND1128 was also compared with that of beta-nicotinamide mononucleotide (beta-NMN). TND1128 induced the branching of axons and dendrites, and increased the number of excitatory synapses. This study provides new insight into TND1128 as a mitochondria-stimulating drug for improving brain function. (C) 2021 Elsevier Inc. All rights reserved.

Automated summary

The study found that TND1128 can promote morphological growth of mouse hippocampal neurons, increase the number of excitatory synapses, and provide a new drug treatment approach for improving brain function.